This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Carmoterol

Chiesi Farmaceutici S.p.A.

Drug Names(s): CHF-4226, TA-2005

Description: Carmoterol is a long-acting, selective 2-adrenergic receptor agonist, provided in a pressurized metered dose inhaler (pMDI) using an HFA propellant.

Deal Structure: Carmoterol is being developed by Chiesi Farmaceutici through a partnership with Tanabe.

In October 2007, Mitsubishi Tanabe Pharma Corporation was formed by the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma Corporation.

Partners: Mitsubishi Tanabe Pharma Corporation


Carmoterol News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug